Author Archives: 瑶 翟

SCN2A: Molecular Mechanisms, NaV1.2 Function, and Precision Therapeutic Strategies for Early-Onset Epilepsy

In April 2025, a clinical case report in Nature Medicine offered groundbreaking evidence for precision therapeutics targeting SCN2A. The study described a neonate with early-onset, drug-resistant epilepsy caused by a gain-of-function (GoF) SCN2A mutation—encoding the α-subunit of the voltage-gated sodium channel NaV1.2. Following intrathecal administration of elsunersen, an SCN2A-targeting antisense oligonucleotide (ASO), the patient experienced a marked reduction in seizure frequency and showed early neurological improvement.

Blog 2025-12-11

November Biopharma BD Highlights: Key M&A and Licensing Deals in 2025

In November 2025, business development (BD) activities in the biopharmaceutical industry slowed slightly compared with October, yet the month still delivered several high-value and strategically important deals. Overall, November’s BD landscape can be summarized by two major themes: large-scale M&A and high-impact licensing agreements. Global pharma companies pursued acquisitions to strengthen pipelines in rare diseases,…

Blog 2025-12-08

Domain-Specific Protein Fragments in Therapeutic Antibody Discovery

Using multiple recombinant protein fragments from the same target—such as extracellular domains, functional regions, and membrane-proximal segments—has become an essential strategy in therapeutic antibody discovery. This approach improves epitope diversity, enhances screening accuracy, reduces conformational bias, and accelerates the identification of high-value antibodies including blockers, agonists, and internalizing antibodies.

Blog 2025-12-08

Limited-Time 50% OFF: 100 μg Human, Monkey, Mouse & Dog Recombinant Proteins

In biomedical research and new drug development, recombinant proteins from three major model species—monkey, mouse, and dog—serve as a vital bridge from basic research to preclinical validation. Mouse recombinant proteins, due to their high compatibility with experimental models, are widely used in studies of immune mechanisms, in vivo pharmacological evaluation, and target validation. Monkey-derived proteins…

News 2025-11-30

Over $76 billion! October Biopharma Deal Review

In October 2025, the global biopharmaceutical sector remained highly active, with innovation-driven collaborations and mergers & acquisitions continuing to heat up. Major deals were struck across diverse areas—including antibody drugs, ADCs, RNA therapeutics, AI-driven drug discovery, autoimmune diseases, gene editing, drug delivery, and neurological disorders—reflecting sustained investor and industry confidence in the biopharma landscape. The…

Blog 2025-11-06

Meet DIMA at SAPA-China 2025!

The SAPA-China 2025 Pharmaceutical Industry Conference will be grandly held from October 31 to November 1, 2025, at the Shishan International Conference Center in Suzhou. Under the theme “Building an Innovative Ecosystem, Opening a New Era in Pharmaceuticals,” the conference will feature one main forum and 45 parallel sub-forums, bringing together nearly 400 top leaders…

Uncategorized 2025-10-28
pages-25 Year End Sale en（1）

Hot Membrane Protein-Nanodiscs: Year-End Sale Now On!

Membrane proteins are key target families in drug discovery, including GPCRs, Claudins (CLDN), Tetraspanins, and transporters, which are involved in signal transduction and substance transport. However, their high hydrophobicity and complex structures often make them unstable in traditional systems.The Nanodisc technology encapsulates membrane proteins within a synthetic lipid bilayer, mimicking the natural membrane environment. This…

News 2025-10-28

TSLP: A Promising Target for Opening a New Chapter in Immunotherapy

On January 10, Harbour BioMed and Kelun-Biotech out-licensed the overseas rights of their jointly developed TSLP antibody HBM9378/SKB378 to Windward Bio. The deal reached a total value of up to USD 970 million. HBM9378/SKB378 is a fully human anti-TSLP monoclonal antibody co-developed by Harbour BioMed and Kelun-Biotech, designed to regulate immune responses by inhibiting the thymic…

Blog 2025-09-28

The New Race to Lose Weight: Next Generation Targets

Weight loss isn’t just about “eating less and exercising more“; it’s also about the molecular dynamics behind it. While GLP-1 drugs have been a global hit over the past few years, the development of weight loss drugs extends far beyond this one. New metabolic targets are constantly being discovered, and research and clinical progress are…

Blog 2025-09-24

Breaking Down WCLC 2025 The Most Talked-About Lung Cancer Targets

The 2025 World Lung Cancer Conference (WCLC) will be held by the International Association for the Study of Lung Cancer (IASLC) in Barcelona, Spain, from September 6th to 9th, 2025. As one of the most influential events in the global oncology community, WCLC provides a platform for academic exchange on the latest research findings and…

Blog 2025-09-18